Progressive multifocal leukoencephalopathy therapy

Area of Science:

• Neurovirology
• Immunology
• Neurology

Background:

• Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic infection caused by the JC virus, typically occurring in individuals with chronic immune deficiency.
• Therapeutic development for PML has been hindered by disease rarity and patient complexity, with antiviral trials showing limited efficacy.
• Historically, PML had a poor prognosis, often leading to fatal encephalitis.

Purpose of the Study:

• To review the current understanding of PML treatment strategies.
• To highlight the shift in PML prognosis and management approaches.
• To discuss the role of immune reconstitution versus antiviral therapy in PML.

Main Methods:

• Review of existing literature on PML.
• Analysis of clinical trial outcomes for antiviral therapies.
• Evaluation of immune reconstitution strategies in managing PML.
• Assessment of the impact of treatments for underlying immune deficiencies (e.g., HIV, natalizumab-associated PML).

Main Results:

• The prognosis for PML has significantly improved, with a majority of patients now surviving.
• Effective immune reconstitution strategies, particularly for HIV and natalizumab-induced PML, have driven this improved outlook.
• Antiviral therapies have not yet demonstrated convincing clinical efficacy in small trials.

Conclusions:

• Optimal immune reconstitution to control JC virus, while carefully managing immune reconstitution inflammatory syndrome (IRIS), is the most practical current approach to treating PML.
• While an effective antiviral therapy remains a goal, current management focuses on restoring the patient's immune system.
• The improved survival rates underscore the importance of addressing the underlying immune deficiency in PML management.